Cargando…
A Novel Probe for Spliceosomal Proteins that Induces Autophagy and Death of Melanoma Cells Reveals New Targets for Melanoma Drug Discovery
BACKGROUND/AIMS: Despite recent advances in melanoma drug discovery, the average overall survival of patients with late stage metastatic melanoma is approximately 3 years, suggesting a need for approaches that identify new melanoma targets. We have previously reported a discovery of novel anti-melan...
Autores principales: | Palrasu, Manikandan, Knapinska, Anna M., Diez, Juan, Smith, Lyndsay, LaVoi, Travis, Giulianotti, Marc, Houghten, Richard A., Fields, Gregg B., Minond, Dmitriy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990463/ https://www.ncbi.nlm.nih.gov/pubmed/31573152 http://dx.doi.org/10.33594/000000164 |
Ejemplares similares
-
Novel Pyrrolidine Diketopiperazines
Selectively Inhibit
Melanoma Cells via Induction of Late-Onset Apoptosis
por: Onwuha-Ekpete, Lillian, et al.
Publicado: (2014) -
The Parallel Structure–Activity Relationship Screening of Three Compounds Identifies the Common Agonist Pharmacophore of Pyrrolidine Bis-Cyclic Guanidine Melanocortin-3 Receptor (MC3R) Small-Molecule Ligands
por: Ericson, Mark D., et al.
Publicado: (2023) -
Spliceosome Mutations in Uveal Melanoma
por: Nguyen, Josephine Q.N., et al.
Publicado: (2020) -
Direct Phenotypic Screening in Mice: Identification
of Individual, Novel Antinociceptive Compounds from a Library of 734 821
Pyrrolidine Bis-piperazines
por: Houghten, Richard A., et al.
Publicado: (2015) -
Discovery and Optimization of Selective Inhibitors of Meprin α (Part I)
por: Hou, Shurong, et al.
Publicado: (2021)